Search

The post-thrombotic syndrome (PTS) is a common, debilitating complication following deep venous thrombosis. PTS is a syndrome for which it has been difficult to provide a clear definition. PTS was defined as chronic venous signs/symptoms after a deep venous thrombosis. A number of scales are available to diagnose PTS, but there is a strong need for standardization. The Villalta scale was chosen as the standardized PTS scale. The Villalta scale has been validated in several studies and shows good correlation with generic and disease-specific quality of life scales. The inter-observer rate between study nurses and physicians was shown to be very good. Furthermore, the scale shows good discriminative properties among the different severity groups of PTS. The Villalta scale is useful for use in randomized controlled trials and it allows pooling of data from different studies. The Villalta scale should undergo further validation on intra-rater reliability. Ongoing randomized controlled trials will further validate the Villalta scale for use in PTS. [ABSTRACT FROM AUTHOR]

Abstract: Objective: One in four patients with primary iliofemoral deep vein thrombosis (DVT) develops post-thrombotic syndrome (PTS) within 1 year despite optimal standard anticoagulant therapy. Removal of thrombus by thrombolytic drugs may prevent PTS. The aim of this study was to assess the short-term safety and efficacy of ultrasound-accelerated catheter-directed thrombolysis (US-accelerated CDT). Design: This was a prospective non-randomised interventional study with US-accelerated CDT for DVT. Patients and methods: Twelve patients with DVT (seven caval–iliofemoropopliteal, three iliofemoropopliteal, one femoropopliteal and one superior caval vein thrombosis) receiving standard anticoagulant and compression therapy, were treated with additional US-accelerated CDT (13 procedures) using the EKOS Endowave® system (EKOS Corporation, Bothell, WA, USA) between October 2008 and January 2010. Results: Thrombolysis was successful in 85% (11/13), with complete clot lysis (>90% restored patency) and in one case with partial clot lysis (50–90% restored patency). No pulmonary embolism and one bleeding at the catheter-insertion site were observed. In three patients, underlying lesions were successfully treated with balloon angioplasty and stent insertion. Four patients developed early recurrent thrombosis due to untreated residual venous obstruction. Conclusion: US-accelerated CDT is a safe and promising treatment in patients with DVT. Residual venous obstruction should be treated by angioplasty and stent insertion to avoid early re-thrombosis. [Copyright &y& Elsevier]